Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics. Angiex targets fundamental aspects of endothelial biology with a focus on angiogenesis; its lead product is an antibody-drug conjugate therapy for cancer. Angiex was launched with IP from Beth Israel Deaconess Medical Center, is resident at LabCentral in Cambridge, and recently closed a $3 million Series A round.
Angiex founders discovered VEGF-A, have been recognized as the world’s leading experts in tumor blood vessel biology, developed new methods for per cell mRNA quantification, founded four companies, and wrote a best-selling diet book. We are looking to team up with creative talents to end the scourge of cancer.
- Paul Jaminet, PhD Chief Executive Officer
- Shou-Ching Jaminet, PhD Chief Scientist
- Harold F. Dvorak, MD Chief Medical Officer